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330Treatment with GM-CSF Secreting Myeloid Leukemia
Cell Vaccine Prior to Autologous-BMT Improves the
Survival of Leukemia-Challenged Mice
Jenny Zilberberg,1 Thea M. Friedman,1 Glenn Dranoff,2 Robert Korngold1Vaccination with irradiated autologous tumor cells, engineered to secrete granulocyte macrophage-colony
stimulating factor (GM-CSF) (GM tumor), can generate potent antitumor effects when combined with autol-
ogous bone marrow transplantation (BMT). That notwithstanding, the post-BMT milieu, characterized by
marked cytopenia, can pose a challenge to the implementation of vaccine immunotherapies. To bypass
this problem, partial post-BMT immune reconstitution has been allowed to develop prior to vaccination.
However, delaying vaccination can also potentially allow the expansion of residual tumor cells. Other
approaches have used reinfusion of ‘‘primed’’ autologous lymphocytes and multiple administrations of GM
tumor cells, which required the processing of large amounts of tumor. Utilizing the MMB3.19 murine myeloid
leukemia model, we tested whether a single dose of GM tumor cells, 7 days prior to syngeneic BMT, could be
a curative treatment in MMB3.19-challenged recipient mice. This vaccination protocol significantly improved
survival of mice by eliciting long-lasting host immune responses that survived lethal irradiation, and were even
protective against post-BMT tumor rechallenge. Furthermore, we demonstrated that mature donor lympho-
cytes can also play a limited role in mounting the antitumor response, but our pre-BMT vaccination strategy
obviated the need for either established de novo immune reconstitution or the use of multiple post-BMT
immunizations.
Biol Blood Marrow Transplant 17: 330-340 (2011)  2011 American Society for Blood and Marrow TransplantationKEY WORDS: AML, Autologous BMT, ImmunotherapyINTRODUCTION
Allogeneic blood and marrow transplantation
(BMT) constitutes one of the few potentially curative
treatments for a number of hematologic malignancies,
including acute myeloid leukemia (AML) [1-3].
Mature donor T cells administered with the graft
play a critical role in enhancing engraftment, fighting
opportunistic infections, and mounting graft-versus-
leukemia (GVL) responses to counteract residual
tumor cells that survive intensive chemotherapy regi-
mens. Although most transplants are performed be-
tween HLA-matched related or unrelated donors,1The John Theurer Cancer Center, Hackensack Univer-
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6/j.bbmt.2010.09.020allogeneic T cells can still mount immune responses
against the different minor histocompatibility antigens
(miHA) that are expressed by a number of host tissues,
leading to graft-versus-host disease (GVHD), one of
the major complications associated with allogeneic
BMT [4-6]. An autologous transplant, on the other
hand, offers the advantage of lower transplant-related
morbidity and mortality as it does not cause GVHD
or utilize immunosuppressive preconditioning drugs,
but it is linked to higher relapse rates because of the
absence of a sufficient GVL effect. Thus, a treatment
modality capable of augmenting the antitumor immu-
nity of autologous T cells represents an attractive
alternative to pursue.
In this regard, a body of preclinical [7-10] and
clinical studies [7,11,12] have shown that the use of
cellular immunotherapy, in the form of vaccination
with irradiated autologous tumor cells engineered to
secrete granulocyte macrophage colony stimulating
factor (GM-CSF) (GM tumor), can generate a potent
antitumor effect when combined with BMT. That
notwithstanding, the post-BMT milieu, characterized
by marked cytopenia, can pose a challenge to the im-
plementation of vaccine immunotherapies [10,13,14].
In an effort to bypass this issue, partial post-BMT
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lowed prior to vaccination [12]. Delaying vaccination,
however, can potentially also allow the expansion of
residual tumor cells. Another recent approach has
been the use of ‘‘primed’’ autologous lymphocytes col-
lected before transplantation for later reinfusions [7]
along with multiple administrations of GM tumor
cells. Yet, the need for multiple injections can bound
the widespread use of this immunotherapy because
collection and processing of large amounts of autolo-
gous tumor cells can be a limiting factor.
To circumvent these issues, the current study
utilizing the MMB3.19 murine leukemia model of
C57Bl/6 (B6) origin [15], was designed to test the pos-
sibility that a single vaccination dose with GM-CSF
secreting MMB3.19 (GM-MMB3.19) cells, 7 days
prior to syngeneic BMT, could be a curative treatment
against an MMB3.19 tumor challenge. Our results in-
dicated that this vaccination protocol can significantly
improve the survival rate of tumor-challenged mice by
eliciting long-lasting host immune responses that sur-
vive lethal irradiation conditioning, and are protective
against post-BMT tumor rechallenge. Furthermore, in
analyzing the mechanisms associated with the success
of this protocol, we demonstrated that mature donor
lymphocytes play only a limited role in the improved
survival of GM-MMB3.19-treated mice, and that the
need for either de novo immune reconstitution or the
use of multiple immunizations can be avoided using
this vaccination strategy.METHODS
Mice
Male C57BL/6 (B6) mice were purchased from
The Jackson Laboratory (Bar Harbor, ME). The
eGFP transgenic (eGFP-Tg) mice, on a B6 back-
ground, were obtained from the laboratory of
Dr. Jon Serody (University North Carolina, Chapel
Hill, NC) and bred in our colony. Donor and recipient
mice between 8 and 12 weeks of age were used in all
experiments. Mice were kept in a pathogen-free envi-
ronment in autoclaved microisolator cages and were
provided with acidified (pH 2.5) water and autoclaved
food ad libitum.Syngeneic Bone Marrow Transplantation
and Tumor Challenge
Phosphate-buffered saline (PBS) supplemented
with 0.1% bovine serum albumin (BSA) was used for
all preparative manipulations of donor cells. Donor
lymphocytes (DL) were prepared as previously de-
scribed [16] from pooled spleen (red blood cell lysed)
and lymph node (LN) cell suspensions from B6 mice.
T cell-depleted (anti-Thy-1.2 mAb-treated) bonemarrow (ATBM) cells were prepared by flushing
bone marrow cells from the femurs of donor mice, fol-
lowed by incubation with J1j mAb and C0 for 45 min-
utes at 37C. Recipients were exposed to 8.5 Gy and
4 hours later transplanted with either 2  106 ATBM
cells alone or in combination with 4-5  106 DL, in-
jected intravenously (i.v.) in PBS (DL numbers were
adjusted to 2  106 CD31 T cells using flow cytomet-
ric [FC] analysis). On day 1 post-BMT, mice were
challenged intraperitonealy (i.p.) with 1  105 B6-
derived MMB3.19 myeloid leukemia cells, as previ-
ously described [17]. Mice were monitored for
morbidity and mortality until the termination of the
experiment, 100 days post-BMT.Mice were autopsied
at the completion of the experiment to confirm the
absence of tumor masses.
Vaccine Preparation and Administration
GM-CSF–secreting MMB3.19 cell (GM-
MMB3.19) were produced using the MFG retroviral
vector, as previously described [18]. The GM-
MMB3.19 cells were irradiated with 40 Gy, washed
2 times with PBS, and injected subcutaneously (s.c.)
in the right flank or via i.p., as indicated (2  105
cells/0.4 mL) 7 days prior to BMT, or on day 1 post-
BMT when indicated. GM-CSF secretion by GM-
MMB3.19 was 100 ng/1  106 cells in 24 hours,
as determined by ELISA. In some experiments, mice
were treated with 2  105, 40-Gy irradiated, non-
GM-CSF—secreting MMB3.19 cells (to be subse-
quently referred to as non-GM-MMB3.19 cells).
Phenotypic Analysis of Host versus Donor
Lymphocytes
B6 mice were vaccinated s.c. with either GM-
MMB3.19 cells, non-GM-MMB3.19 cells, or PBS
(vehicle) and transplanted 7 days later with ATBM
and DL from B6eGFP1 mice. Three weeks post-
BMT, cell suspensions from the skin-draining inguinal
LN were prepared in FC staining buffer (PBS, 0.5%
BSA, 0.1% sodium azide) and analyzed in a Beckman
Coulter FC500 flow cytometer (Brea, CA). FC analysis
was conducted to determine CD41/CD81 T cell
ratios in both donor (eGFP1) and host (eGFP2) pop-
ulations, the percentage of memory (CD441) T cells,
and the percentage of dendritic cells (as determined
by the % CD11c1 cells in the myeloid gate  [% size
of the myeloid gate]/100), in both donor and host
subsets. All mAb (PE or PE-Cy5-conjugated, or
biotinylated mAb to mouse CD4, CD8, CD44, and
CD11c were purchased from BD Biosciences (San
Jose, CA).
Rechallenge Experiments
In some experiments, vaccinated mice that sur-
vived the initial tumor challenge with 1  105
332 Biol Blood Marrow Transplant 17:330-340, 2011J. Zilberberg et al.MMB3.19 cells, were rechallenged at$12 weeks post-
BMT with 5  106 tumor cells. For control purposes,
corresponding ATBM mice were also challenged with
an equal amount of tumor cells. This tumor burden
was chosen because of the fact that lower dosages
of MMB3.19 cells can be rejected in immune-
competent mice (data not shown). Mice were subse-
quently monitored for morbidity and mortality for
an additional 100 days, until the termination of the ex-
periment, when they were autopsied to confirmed the
absence of tumor masses.
For rechallenge experiments following adoptive
transfer, splenocytes, LN, and BM cells were harvested
from vaccinated mice that survived initial tumor chal-
lenge or from their corresponding ATBM controls.
Preparation of DL and ATBM cells was performed,
as described above. Recipient mice were exposed to
8.5 Gy and 4 hours later transplanted with 2  106
ATBM cells along with 4-5 106DL (from either vac-
cinated or ATBM donors), followed by challenge on
day 1 post-BMT, with 1  105 MMB3.19 cells.
Statistical Analysis
For statistical analysis of survival plots, Kaplan-
Meier survival and the nonparametric log-rank
(Mantel-Cox), or Wilcoxon signed rank test were
performed. Data were pooled from 2 to 3 separate
experiments consisting of 5 to 10 mice per group as
indicated in each figure legend. Cox proportional haz-
ards test was conducted to determine whether there
was interaction between groups and time as previously
described [19,20]. Data was stratified by time for
subsequent log-rank analysis, when interaction was
statistically significant (P\ .05). For statistical analysis
of FC data, nonparametric Kruskal-Wallis ANOVA
was used to compare all groups, followed by Dunn’s
multiple comparison test on individual pairs when anal-
ysis of variance (ANOVA) testwas statistically significant
(P\.05).Datawere analyzed inGraphPadPrism (v. 4.0)
or SAS (v. 9.2).0 10 20 30 40 50 60 70 80 
0
10
20
30
40
50
60
70
80
90
100
110
Days post-BMT 
%
 
S
u
r
v
i
v
a
l
 
Figure 1. Effect of pre-BMT vaccination with GM-MMB3.19 or non-GM-MM
were vaccinated with a single s.c. dose of 2 105 GM-MMB3.19 or non-GM-M
hours later transplanted with either B6 syngeneic 2 106 ATBM cells alone (AT
(DL, GM-MMB3.19 post- and pre-BMT1 DL and non-GM-MMB3.19 pre-BMT
were challenged with an i.p. injection of 1  105 MMB3.19 cells. The GM-MMB
MMB3.19 cells on day 1 post-BMT. Data were pooled from 2 to 3 separate exRESULTS
GVL Reactivity to MMB3.19 Leukemia Cells in
Mice Vaccinated with GM-MMB3.19 Cells or
Non-GM-MMB3.19 Cells
The GVL effect of a single pre-BMT vaccination
dose of either GM-MMB3.19 or non-GM-MMB3.19
cells was examined in combination with a syngeneic
BMT, against a MMB3.19 tumor challenge. To this
end, 8- to 12-week-old male B6 mice were vaccinated
s.c. in the right flank with either 2  105 irradiated (40
Gy) GM-MMB.319 (secreting 100 ng/1 106 cells/24
hours) or irradiated (40 Gy) non-GM-MMB3.19 cells
(Figure 1 and Table 1). One week posttreatment, all
mice were exposed to lethal irradiation (8.5 Gy) and
4 hours later transplanted with 2  106 syngeneic B6
ATBM cells along with 4-5  106 DL. On day 1, all
mice (except ATBM; the engraftment control) were
challenged i.p. with 1  105 viable MMB3.19 cells to
mimicminimal residual tumor burden following a clin-
ically relevant preconditioning regimen and BMT.
The tumor-challenged mice that were transplanted
with either ATBM alone (MMB3.19) or along with
DL (DL) served as the unvaccinated control groups.
Vaccinated groups (pre-BMT or post-BMT), all
received ATBM 1 DL at the time of transplant and
were tumor-challenged on day 1. The MMB3.19
group had a median survival time (MST) of 21 days
and 100% mortality by day 38 (Figure 1 and Table
1). In comparison, theDL group had a small but signif-
icant increase in its survival rate (MST of 27 days and
12% 100-day survival, P\ .01). Pre-BMT vaccination
with irradiated MMB.319 cells provided a significant
advantage (MST of 37.5 days and 25% survival) com-
pared to unvaccinatedDLmice (P5 .03). On the other
hand, DL transplantation along with post-BMT vacci-
nation did not provide any increase in theMST or sur-
vival rate (14.3%) compared to the DL group (P .
.05). Most notably, mice treated with GM-MMB3.19
cells 7 days pre-BMT exhibited a significantly greater90 100 
ATBM 
 MMB3.19 
 DL 
 GM-MMB3.19 post-BMT + DL 
 GM-MMB3.19 pre-BMT + DL 
non-GM-MMB3.19 pre-BMT + DL
B3.19 cells on GVL responses to MMB3.19 leukemia challenge. B6 mice
MB3.19 tumor cells. One week later, mice were exposed to 8.5 Gy and 4
BM andMMB3.19 groups) or in combination with 4-5 106 lymphocytes
1 DL groups). On day 1 post-BMT, all groups except the ATBM control
3.19 post-BMT group was vaccinated with a single dose of 2  105 GM-
periments consisting of 5 to 10 mice per group.
Table 1. Statistical Comparison between Groups from Figure 1
Groups Compared MST (Days) and Survival Rate (%) P Value
DL versus MMB3.19 27, 12% versus 21, 0% <.01
GM-MMB3.19 post-BMT + DL versus DL 26.5, 14.3% versus 27, 12% NS (0.8)
GM-MMB3.19 pre-BMT + DL versus DL 52% versus 27, 12% <.01
GM-MMB3.19 pre-BMT + DL versus GM-MMB3.19 post-BMT + DL 52% versus 26.5, 14.3% <.01
non-GM-MMB3.19 pre-BMT + DL versus DL 37.5, 25% versus 27, 12% 5.03
GM-MMB3.19 pre-BMT + DL versus non-GM-MMB3.19 + DL 52% versus 37.5, 25% 5.03 (stratified: $30 days)*
Groups were compared using nonparametric log-rank test.
*Cox proportional hazards test P < .01.
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DL, post-BMT vaccination, or non-GM-MMB3.19
cells pre-BMT groups (P \ .01, P \ .01 and P 5
.03, respectively) (Table 1).
Role of Syngeneic Donor Lymphocytes in the
Survival of pre-BMT Vaccinated Recipient Mice
The results presented in Figure 1 suggested that
syngeneic DL in combination with pre-BMT vaccina-
tion with GM-MMB3.19 significantly improved the
survival rate of MMB3.19 tumor-challenged mice.
To better understand the role of DL in the current
GM-CSF secreting AML vaccine model, we compared
the effects of vaccination in mice transplanted with
ATBM cells alone or in combination with DL
(Figure 2 and Table 2). In addition, we also tested the
GVL effects of non-GM-MMB3.19 cells under these
same conditions. As in the previous experiment, the un-
vaccinated control groups were transplanted with
ATBM cells alone (MMB3.19) or ATBM and DL
(DL) and challenged with MMB3.19 cells on day 1.
The other 4 groups were vaccinated with irradiated
GM-MMB3.19 or MMB3.19 cells 7 days prior to
BMT and subsequently challenged with tumor on
day 1 (ie, GM-MMB3.19 pre-BMT 1 DL, non-GM-
MMB3.19 pre-BMT 1 DL, GM-MMB3.19 pre-
BMT [no DL] and non-GM-MMB3.19 pre-BMT
[no DL]). Comparisons between groups indicated that0 10 20 30 40 50 60 70 80 9
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Figure 2. Role of syngeneic DL in the GVL response to MMB3.19 leukemia ch
vaccination. B6 mice were vaccinated with a single dose of 2 105 GM-MMB3.1
Gy and 4 hours later transplanted with either B6 syngeneic 2 106 ATBM cells
MMB3.19 pre-BMT [no DL] groups) or in combination with 4-5  106 lympho
groups). On day 1 post-BMT, all groups except the ATBM control were challeng
2 to 3 separate experiments consisting of 5 to 10 mice per group.DL enhanced the effect of GM-MMB3.19 vaccination,
as determined by the increased survival rate of the
GM-MMB3.19 pre-BMT 1 DL group (53%) versus
GM-MMB3.19 pre-BMT (no DL) (33%) mice. This
increasewas statistically significant (P5 .044), as deter-
mined by Wilcoxon signed rank test, which is best at
detecting differences that occur at early points in time
(Table 2). Non-GM-MMB3.19 1 DL mice also
experienced significantly greater survival rates (25%)
compared to their no DL counterparts (0%), using
the log-rank test, which is more sensitive to differences
that occur at later time points. Furthermore, when
the data were analyzed $28 days post-BMT (at which
time point the survival curves no longer overlapped)
(Table 2), GM-MMB3.19 pre-BMT–vaccinated (no
DL) mice experienced significantly greater survival
rates than the DL control group (P\ .01), underscor-
ing the potential contribution of non-DL (ie, host ele-
ments) to the GVL effect of GM-CSF–secreting tumor
in the current pre-BMT vaccination model. Survival of
the non-GM-MMB3.19 pre-BMT (no DL) group, on
the other hand, was not improved, and actually was sig-
nificantly less compared to that of control DLmice (0%
versus 10.5% respectively; P 5 .02). Finally, GM-
MMB3.19 pre-BMT (no DL) mice had significantly in-
creased survival compared to the non-GM-MMB3.19
pre-BMT (no DL) group (33% versus 0% respectively;
P\ .01) (Table 2), suggesting that the GVL effect of0 100
 MMB3.19
 DL
ATBM
GM-MMB3.19 pre-BMT + DL
GM-MMB3.19 pre-BMT (no DL)
non-GM-MMB3.19 pre-BMT + DL
non-GM-MMB3.19 pre-BMT (no DL)
allenge associated with GM-MMB3.19 and non-GM-MMB3.19 pre-BMT
9 or non-GM-MMB3.19 cells. One week later, mice were exposed to 8.5
alone (ATBM, MMB3.19, GM-MMB3.19 pre-BMT [no DL] and non-GM-
cytes (DL, GM-MMB3.19 pre-BMT1 DL, and non-GM-MMB3.191 DL
edwith an i.p. injection of 1 105 MMB3.19 cells. Datawere pooled from
Table 2. Statistical Comparison between Groups from Figure 2
Groups Compared MST (Days) and Survival Rate (%) P Value
DL versus MMB3.19 28, 10.5% versus 21.5, 0% <.01
GM-MMB3.19 pre-BMT + DL versus DL 53.3% versus 28.0, 10.5% <.01
GM-MMB3.19 pre-BMT (no DL) versus DL 27.5, 33 % versus 28.0, 10.5% <.01 (stratified: $ 28 days)*
GM-MMB3.19 pre-BMT + DL versus GM-MMB3.19 pre-BMT (no DL) 53.3% versus 27.5, 33.0% 0.1 (log-rank) and .044†
non-GM-MMB3.19 pre-BMT + DL versus non-GM-MMB3.19 pre-BMT (no DL) 37.5, 25% versus 23.5, 0% <.01
DL versus non-GM-MMB3.19 pre-BMT (no DL) 28, 10.5% versus 23.5, 0% .02
GM-MMB3.19 pre-BMT (no DL) versus non-GM-MMB3.19 pre-BMT (no DL) 27.5, 33% versus 23.5, 0% .01
Groups were compared using nonparametric log-rank test.
*Cox proportional hazards test P < .01.
†Comparison was performed using Wilcoxon signed rank test
334 Biol Blood Marrow Transplant 17:330-340, 2011J. Zilberberg et al.the latter group was strongly dependent on the
presence of DL.
Role of Host T Cells in the Survival
of Pre-BMT—Vaccinated Recipient Mice
The improved survival rate exhibited by GM-
MMB3.19 pre-BMT vaccinated recipient mice in the
absence of DL suggested that host immune cells that
survive irradiationmust contribute to the antitumor re-
sponse, an effect not present in mice vaccinated with
non-GM-MMB3.19 cells that had 0% survival in the
absence of DL (Figure 2). To further elucidate the
mechanism associated with the increased survival in
GM-MMB3.19–vaccinated mice, recipients were
treated with 0.2 mL of GK1.5 (1:6 ratio) and 2.43
(1:50 ratio) mAb for depletion of CD41 and CD81 T
cells, respectively, 4 days prior to vaccination with
irradiated GM-MMB3.19 cells (11 days pre-BMT).
Examination of spleen and LN cells using FC analysis
indicated that, at time of vaccination, the depleted
subsets constituted \1% of the total lymphocyte
population. In addition, we verified that administration
of these mAb did not deplete the transplanted DL
(data not shown). Upon vaccination, these recipients
exhibited equivalent survival to that of nonvaccinated
control mice (DL), suggesting that pre-BMT vaccina-
tion induced GVL effects were predominantly0 10 20 30 40 50 60 70 8
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Figure 3. RoleofhostT cells in theGVLeffect following pre-BMTvaccinationwi
2.43 (1:50)mAbagainstCD41 andCD81Tcells, respectively, 4 days prior to vacc
(11 days after T cell depletion), the mice were exposed to 8.5 Gy and 4 hours late
MMB3.19, andGM-MMB3.19 pre-BMTnoDL (T depleted host) groups] or in com
andGM-MMB3.19 pre-BMT1DL[Tdepletedhost] groups).Onday 1 post-BMT,
1  105 MMB3.19 cells. Data were pooled from 2 to 3 separate experiments comediated by host T cells that survived irradiation
conditioning. In these experiments, we also observed
a significant difference in the survival of the GM-
MMB3.19–vaccinated/non-T cell–depleted 1 DL
group (50%) compared to GM-MMB3.19–vaccinated/
T cell–depleted 1 DL recipients (6.7%), and between
each of these groups and GM-MMB3.19/T cell–
depleted (no DL) mice (0% survival) (P\ .01, respec-
tively) (Figure 3 and Table 3).
Phenotypic Analysis of Host versus Donor
Lymphocytes after Vaccination with Irradiated
GM-MMB3.19 or Irradiated MMB.319 Cells
To further examine themechanism associated with
the GVL effects of GM-MMB3.19 cells in the current
model, pre-BMT s.c. vaccinated mice (treated with
either GM-MMB3.19 cells, non-GM-MMB3.19 cells,
or vehicle PBS) were transplanted with ATBM 1 DL
obtained from eGFP mice. In doing so, host immune
cells surviving irradiation and not carrying the eGFP
marker were easily distinguishable from DL given
at time of transplant, as well as the de novo donor-
derived cells. Three weeks post-BMT, single-cell sus-
pensions from the draining inguinal LNwere prepared
from individual mice for FC analysis to compare CD4/
CD8 ratios and expression of CD44high (a memory
marker) on T cell subsets, as well as the percentage0 90 100 
ATBM 
MMB3.19 
GM-MMB3.19  pre-BMT + DL 
(T depleted host) 
GM-MMB3.19  pre-BMT + DL 
GM-MMB3.19 pre-BMT no DL
(T depleted host) 
DL 
thGM-MMB3.19cells. B6micewere treatedwith0.2mLofGK1.5 (1:6) and
inationwith a single s.c. doseof2 105GM-MMB3.19 cells.Oneweek later
r transplanted with either B6 syngeneic 2 106 ATBM cells alone (ATBM,
binationwith 4-5 106 lymphocytes (DL, GM-MMB3.19 pre-BMT1DL,
all groups except theATBMcontrolwere challengedwith an i.p. injectionof
nsisting of 5 to 10 mice per group.
Table 3. Statistical Comparison between Groups from Figure 3
Groups Compared MST (days) and Survival Rate (%) P Value
DL versus MMB.319 28, 0% versus 21, 0% <0.01
DL versus GM-MMB3.19 pre-BMT + DL (T depleted host) 28, 0% versus 31, 6.7% NS (.23)
DL versus GM-MMB3.19 pre-BMT + DL (T depleted host) 95.5, 50% versus 30.5, 6.7% <.01
GM-MMB3.19 pre-BMT + DL (T depleted host) versus
GM-MMB3.19 pre-BMT + no DL (T depleted host)
30.5, 6.7% versus 21, 0% <.01
Groups were compared using nonparametric log-rank test.
Figure 4. Percentage of CD11c1eGFP2 cells in the skin-draining LN of
vaccinated mice. B6 mice were vaccinated with a single dose of 2  105
GM-MMB3.19, non-GM-MMB3.19 cells, or PBS alone. One week later,
mice were exposed to 8.5 Gy and 4 hours later transplanted with
ATBM and lymphocytes from eGFP1B6 syngeneic mice in order to be
able to differentiated between host (eGFP2) and donor cells (eGFP1).
Three weeks post-BMT, cell suspensions from the skin-draining LN of
individual mice were prepared for flow cytometric analysis to determine
the percentage of CD11c1-expressing cells. Data were pooled from 2
separate experiments consisting of 3 to 6 mice per group. Statistical dif-
ference between groups was determined using Kruskal-Wallis 1-way
ANOVA analysis (P \ .01) followed by Dunn’s multiple comparison
test on individual pairs (*P\.05, **P\.01).
Biol Blood Marrow Transplant 17:330-340, 2011 335GM-CSF Secreting Autologous Tumor Vaccineof eGFP2 (host) and eGFP1 (donor) DCs (as deter-
mined by the expression of CD11c in the myeloid
gate). Statistical analysis showed that 3 weeks post-
BMT (4 weeks postvaccination) mice treated with
GM-MMB3.19 cells presented with a significant
increase in the mean expression of CD11c in the
eGFP- population (1.97 6 0.33%) (Figure 4) com-
pared to mice that received PBS (0.89 6 0.37%;
P\ .01) or non-GM-MMB3.19 cells (1.31 6 0.39%;
P \ .05). The CD11c expression in the non-GM-
MMB3.19–treated group, although higher, was not
statistically significant (P . .05) compared to PBS-
treated mice. On the other hand, the percentage of
DCs in the donor cell population (eGFP1) was compa-
rable between the 3 groups (PBS5 0.266 0.15%GM-
MMB3.19 5 0.25 6 0.2%, non-GM-MMB3.19 5
0.3 6 0.26%). Likewise, CD41/CD81 ratios and
memory (CD44high) expression in either T cell subset
were found to be similar between groups (Table 4).
Effect of Vaccination Site on the Survival Rate of
MMB3.19 Myeloid Leukemia Challenged Mice
The s.c. route was chosen as the preferred method
of vaccination in the conducted studies for its clinical
translatability. However, in lieu of the fact that in the
current murine AML model, tumor cells were injected
i.p., experiments were conducted to assess the effective-
nessof i.p. vaccination, at the site of tumor challenge.To
this end,micewere treated, as previously described,with
either an i.p. or a s.c. injection of 1 105 irradiatedGM-
MMB3.19 cells 7 days pre-BMT (Figure 5 andTable 5).
The results from these experiments showed that animals
receiving i.p. vaccinationhada survival rateof85%com-
pared to 50% in s.c. vaccinated mice; a difference that
was statistically different (P5 .04). Both s.c. and i.p. vac-
cination routes significantly improved the survival rate
of MMB3.19-challenged mice compared to the control
DL group.
Rechallenge of Surviving GM-MMB3.19
Vaccinated Mice
The long-lasting effects of vaccination were evalu-
ated by either adoptive transfer of cells obtained from
surviving mice, or by challenging vaccinated mice
(ie, GM-MMB3.19–treated recipients that survived
the initial 1  105 MMB3.19 tumor challenge), and
their corresponding ATBM controls (Figure 6), witha tumor burden of 5  106 cells. Mice that were trans-
planted with cells (ATBM and DL) from surviving
mice that had been treated with GM-MMB3.19
and challenged on day 1 post-BMT with 1  105
MMB3.19 cells did not experience increased survival
rates compared to mice that were transplanted with
cells obtained from reconstituted ATBM mice. On
the other hand, 84% of s.c. vaccinated mice survived
tumor rechallenge, compared to 50% of i.p. vaccinated
and 36% of control ATBM mice (P 5 0.02 and P\
.01, respectively) (Table 6). No statistical difference
(P 5 .52) was found between rechallenged (i.p.) and
ATBM groups.DISCUSSION
As demonstrated in our studies, the successful im-
plementation of a tumor vaccine relies on the delivery
strategy selected. Understanding the mechanism
Table 4. Percentage Expression of T Cell Subsets in the Host (eGFP-) and eGFP+ Populations
(Mean Percentage Expression ± SD)
Phenotype Control (PBS) GM-MMB3.19 non-GM-MMB3.19
CD4eGFP+/CD8eGFP+ 2.29 ± 1.56 2.15 ± 1.07 2.03 ± 0.79
CD4eGFP2/CD8eGFP2 3.06 ± 1.37 3.82 ± 0.56 3.13 ± 0.91
CD4+CD44higheGFP+ 2.85 ± 1.15 2.77 ± 1.21 2.74 ± 1.05
CD4+CD44higheGFP2 1.68 ± 0.91 1.49 ± 0.70 1.50 ± 0.58
CD8+CD44higheGFP+ 2.23 ± 2.03 2.38 ± 1.56 2.16 ± 1.56
CD8+CD44higheGFP2 0.50 ± 0.35 0.46 ± 0.17 0.52 ± 0.20
Groups were compared using Kruskal-Wallis ANOVA test. No statistical differences were found for either phenotype.
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widespread implications for the clinical translatability
of this immunotherapeutic approach, and warrants
further investigation. Using a murine model of AML,
we developed a novel and simplified vaccination strat-
egy that consisted of a single dose of GM-CSF–
secreting autologous tumor, 7 days prior to BMT.
Without the need for multiple post-BMT treatments
[7,12], full donor-derived immune reconstitution
[10,11], or infusion of ‘‘primed’’ lymphocytes, as
previously described by others [7,9,13], we were able
to increase the survival rate of MMB3.19 tumor-
challenged mice. Survival rates increased from a maxi-
mum of 12% (achieved by transplantation of syngeneic
DL alone) to 50 to 53% (Figures 1-3) following s.c., or
80% (Figure 5) following i.p. pre-BMT vaccination
with GM-MMB3.19 cells. Post-BMT vaccination on
day 1 (Figure 1), however, did not improve the survival
rate of tumor-challenged mice. This result is in agree-
ment with Borrello et al. [13] and Teshima et al. [10],
who, using 2 different murine models, found that post-
BMT donor reconstitution was needed prior to
GM-CSF–secreting tumor immunotherapy in order
to observe a significant antitumor response. Presum-
ably, day 1 post-BMT vaccination failed because
although it takes time for the immune response to
peak following vaccination, the tumor cells have al-
ready started to expand during this time period.
Thus, the tumor growth may outpace the immune0 10 20 30 40 50 60 70 80
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Figure 5. Effect of vaccination site on the survival rate of MMB3.19 myeloid le
dose of 2 105 GM-MMB3.19 cells. One week later, mice were exposed to 8.5
alone (ATBM and MMB3.19 groups) or in combination with 4-5  106 lympho
post-BMT, all groups except ATBM controls were challenged with an i.p. injec
experiments consisting of 5 to 10 mice per group.response, and/or the tumor cells may inhibit the im-
mune response by a variety of immune regulatory
mechanisms [21]. Likewise, and as demonstrated
by others [7,12], multiple vaccinations may be
required to generate optimal T cell responses when
administration is done post/preconditioning and
BMT. In addition, we also observed no difference in
the survival rate of GM-MMB3.19–treated animals
that received wild-type ATBM or TCRKO bone mar-
row cells (unpublished results), further suggesting that
de novo, thymic-derived immune cells may have little
contribution to the GVL effect under the current
vaccination protocol.
The GVL effect of pretreatment with irradiated
(non-GM-CSF secreting) MMB3.19 cells was tested as
well, because it has previously been demonstrated that
irradiated autologous tumor cells have antitumor capa-
bilities [18]. In our model, the use of non-GM-
MMB3.19 cells provided only a small, albeit significant,
improvement in survival (25%) of AML-challenged
mice compared to mice that received DL alone (12%)
(Figure 1 and Table 1). That notwithstanding,
pre-BMT vaccination with GM-MMB3.19 proved to
be a far superior immunotherapy (52% survival)
(Figure 1 and Table 1). The survival rates of the GM-
MMB3.19 versus non-GM-MMB3.19 pretreated
mice suggested that at early time points (\4 weeks
post-BMT) the 2 therapies yield similar outcomes;
however, the effects of GM-CSF immunotherapy90 100
GM-MMB3.19 pre-BMT + DL (i.p)
GM-MMB3.19 pre-BMT + DL (s.c)
MMB3.19
DL
ukemia-challenged mice. B6 mice were vaccinated with a single s.c. or i.p.
Gy and 4 h later transplanted with either B6 syngenic 2 106 ATBM cells
cytes (DL, GM-MMB3.19 pre-BMT 1 DL s.c. and i.p. groups). On day 1
tion of 1  105 MMB3.19 cells. Data were pooled from 2 to 3 separate
Table 5. Statistical Comparison between Groups from Figure 5
Groups Compared MST (Days) and Survival Rate (%) P Value
DL versus MMB.319 25, 4% versus 20.5, 0% 5.013
GM-MMB3.19 pre-BMT + DL (s.c.) versus MMB3.19 + DL 77, 50% versus 25, 4% <.01
GM-MMB3.19 pre-BMT + DL (i.p.) versus MMB3.19 + DL 85% versus 25, 4% <.01
GM-MMB3.19 pre-BMT + DL (i.p.) versus GM-MMB3.19 pre-BMT + DL (s.c.) 85% versus 77, 50% 5.04
i.p. indicates intraperitoneal; sc, subcutaneous.
Groups were compared using nonparametric log-rank test.
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did not elicit a sustained response, resulting in signifi-
cant survival differences between these 2 groups at later
post-BMT time points.
The contribution of DL to the overall GVL re-
sponse, as summarized in Figure 2 and Table 2,
revealed that DL improved the survival of GM-
MMB3.19–vaccinated mice (53.3% in the presence
of DL, versus 33% in their absence), but that its syner-
gistic effect had greater bearing soon after transplanta-
tion (\35 days post-BMT), underscoring the limited,
yet, significant antitumor effect of DL in our model.
Similarly, the finding that survival of GM-MMB3.19
vaccinated (no DL) mice was significantly greater
than that of the control DL group, only when the
statistical comparison was performed at $28 days
post-BMT (Figure 2 and Table 2), also supported
the idea, as suggested by others [13], that syngeneic
mature DL and recent thymic emigrants may have
a greater role at early post-BMT time points, when
the number of residual tumor cells are low and antitu-
mor T cells may be at a minimal proliferative state.
Interestingly, DL were actually indispensable to
irradiated tumor-treated mice, as suggested by the sig-
nificant increase in the survival rate of the pretreated
non-GM-MMB3.19 1 DL group (25%) compared
to the no DL counterpart (0% survival). An observa-
tion further supported by the fact that the survival of
pretreated non-GM-MMB3.19 (no DL) mice was sig-
nificantly inferior to that of control mice receiving DL0 10 20 30 40 50 60 70 80
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
Days Post Tumor Challenge 
%
 
S
u
r
v
i
v
a
l
 
Figure 6. Rechallenge of surviving GM-MMB3.19–vaccinated mice. Surviving G
MMB3.19 cells (i.p.) at$12 weeks post-BMT, or were used as donors for adop
purposes, their ATBM counterparts were also challenged with an equal dosage
Adoptive transfer datawere pooled from 2 different experiments of 10 mice pe
consisting of 3 to 5 mice per group.alone (0% versus 10.5%, respectively) (Figure 2 and
Table 2). These observations supported the assertion
that non-GM-CSF–secreting tumor cells were not
capable of eliciting a sustained immune response;
hence the greater significance of DL to the antitumor
effect in non-GM-MMB3.19–treated mice.
The observation that a single pre-BMT vaccina-
tion was able to produce a significant GVL response
in the absence of DL (Figure 2) led us to hypothesize
that host immune cells surviving myeloablative pre-
conditioning were key to this response. Indeed, deple-
tion of host T cells (Figure 3) greatly compromised the
benefits of GM-CSF–secreting tumor vaccination in
our model, as demonstrated by the fact that GM-
MMB3.19 pretreated/T cell-depleted recipients only
experienced 6.7% survival and were not significantly
different from unvaccinated control (DL) mice. These
results are in agreement with previously reported stud-
ies where depletion of T cells in melanoma-challenged
mice severely reduced the systemic immunity provided
by the vaccine [18]. Taken together, the data from
Figures 2 and 3 demonstrated that host T cells were
critical to the GVL effect produced by pre-BMT vac-
cination withGM-CSF–secreting tumor, and that syn-
geneic mature donor T cells may have had a greater
effect in the early post-BMT period.
DCs are potent antigen-presenting cells (APCs),
and upon appropriate stimulation, matured DCs mi-
grate to the secondary lymphoid tissues where they
can present tumor antigens to T cells and induce 90 100 
ATBM (adoptive transfer) 
GM-MMB3.19 (adoptive transfer) 
ATBM (tumor challenged controls)
GM-MMB3.19 s.c (rechallenged) 
GM-MMB3.19 i.p (rechallenged) 
M-MMB3.19 vaccinated (i.p. or s.c.) mice were rechallenge with 5 106
tive transfer of 2 106 ATBM cells along with 4-5 106 DL. For control
of tumor cells or were used as donors in adoptive transfer experiments.
r group. Rechallenge datawere pooled from 4 to 5 different experiments
Table 6. Statistical Comparison between Groups from Figure 6
Groups Compared MST (Days) and Survival Rate (%) P Value
GM-MMB3.19 s.c. (rechallenged) versus ATBM controls 84% versus 40.5, 36% <.01
GM-MMB3.19 i.p. (rechallenged) versus ATBM controls 82, 50% versus 40.5, 36% .52
GM-MMB3.19 s.c. (rechallenged) versus GM-MMB3.19 i.p. (rechallenged) 84% versus 82, 50% .024
GM-MMB3.19 s.c. (adoptive transfer) versus ATBM (adoptive transfer) 20, 10% versus 20, 10% NS
i.p. indicates intraperitoneal; sc, subcutaneous.
Groups were compared using nonparametric log-rank test.
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strated a dramatic increase of CD11c1 cells in the
spleen of GM-CSF–secreting tumor vaccinated mice,
14 days after treatment, and they went on to prove
that these cells had higher levels of B7-1 and were
more effective at eliciting systemic antitumor immu-
nity. Here, we are the first to demonstrate increased
expression of host-derived DCs at a later time point
(4 weeks postvaccination) after BMT using this immu-
notherapy (Figure 4). Taken together, these results
suggest that these cells are key to the observed long-
lasting GVL effects induced by GM-MMB3.19 cells
in our model. Additionally, given that we did not ob-
serve a statistically significant increase in the number
of DCs between the mice treated with non-GM-
MMB3.19 tumor cells and those treated with PBS,
this would suggest that irradiated tumor cells alone
are less capable of producing a sustained immune re-
sponse via DC expansion.
The existence of functional host-derived radiore-
sistant T cells of both memory and na€ıve phenotype
has been documented [24,25]; thus, we also wanted
to determine whether the improved survival of GM-
MMB3.19–treated mice could be associated to differ-
ences in the eGFP2/eGFP1 (host/donor) T cell ratios
or a greater percentage of memory T cells (as defined
by the expression of CD44high) in either the eGFP1
or eGFP2 compartments. Interestingly, all 3 groups
had comparable amounts of these markers (Table 4).
These results seemed to indicate a lack of increase in
host-derived T cells (particularly of memory pheno-
type) in vaccinated mice, at least at the analyzed time
point. It is possible that by this time point, 3 weeks
post-BMT, the number of antitumor/host-derived T
cells was already diluted by homeostatic proliferation
of DL and de novo thymic emigrants making it more
difficult to quantify their potentially small presence.
In fact, in support of this hypothesis, Borrello et al.
[13] demonstrated that T cell peripheral reconstitution
ultimately diluted the percentage of tumor-antigen-
specific T cells in their model. Further analysis at an
earlier time point (3-5 days post-BMT), including
other memory cell surface markers such as CD62L
and CCR7, should determine whether there are differ-
ences in the percentage of na€ıve, effector memory
(CD44highCCR7highCD62Llow) and central memory
(CD44highCCR7highCD62Lhigh) T cells [26-28] in
either the donor or host populations among theexperimental groups. Likewise, given that T cells (in
particular, those of host origin) were shown to be
critical to the antitumor response in our model
(Figure 3) and by others [18], we also hypothesize
that in combination with the generation of long-
lasting tumor antigen-presenting DCs, vaccination
with GM-MMB3.19 cells best promotes specific
leukemia-reactive host T cells that remain viable after
irradiation and greatly contribute to the GVL effect.
Additional studies utilizing CDR3-size spectratype
analysis [29] are currently underway in our laboratory
to evaluate potential TCR Vb repertoire diversity dif-
ferences between GM-MMB3.19–treated and naive
mice to evaluate antitumor reactivity.
Historically, GM-tumor vaccination has been ad-
ministered via s.c. or intradermal injection. Because
in our AML murine model, tumor challenge was via
the i.p. route, we also tested the GVL effects of a single
i.p. administration of GM-MMB3.19 cells (Figure 5).
The results of these experiments indicated that i.p.
vaccination generated a stronger GVL response than
s.c. vaccination (80% versus 50% survival, respec-
tively). This difference was statistically significant
(Table 5), potentially because circulating T cells en-
countered the tumor antigens and become activated
in the peritoneal compartment, where the tumor
grows. Interestingly, however, when surviving mice
were rechallenged 12 weeks post-BMT (Figure 6),
only mice that were injected s.c. survived the rechal-
lenge at significantly greater rates than their ATBM
counterparts. Subcutaneous vaccination elicits the
activation and maturation of dermal DCs (dermal lan-
gerin(2) and dermal langerin(1) DCs) and Langer-
hans cells (LCs; bone marrow-derived epidermal
DCs), which then migrate to the regional LN to initi-
ate systemic immune responses by presenting pro-
cessed tumor antigens to T cells [30-32]. FC analysis
showed increased host-derived DC expression in the
skin-draining inguinal LN to the injection site in s.c.
GM-MMB3.19 vaccinated mice, observed even 4
weeks postvaccination (Figure 4). Similar observations
were reported by Merad et al. [33], who demonstrated
that after a congenic BMT, no LC chimerism was de-
tectable in the skin for more than 6 months, despite
rapid chimerism in BM, spleen, and LN. In contrast
to the skin, in other epithelia, such as the gut and the
airways, DCs were found to be quickly replaced by
BM-derived precursors, thus demonstrating that the
Biol Blood Marrow Transplant 17:330-340, 2011 339GM-CSF Secreting Autologous Tumor Vaccineanatomic origin can affect not only the function but
the life span of DCs [34,35]. Finally, it has also been
shown that despite the rapid turnover of individual
mature DCs, some DC precursors are capable of
transmitting internalized processed antigens to
successive generations of their progeny during cell
division, which can then present effectively to
antigen-specific T cells [36]. Taken together, these
findings further substantiate the possibility that
antigen-loaded DCs, present at the skin, persist over
time in our model and are critical to the antitumor re-
sponses upon rechallenge associated with s.c. vaccina-
tion. Therefore, it is likely, that a combined regimen of
vaccination near or at the site of tumor growth (an
alternative that is more applicable to solid tumors)
along with dermal (s.c. or intrademal) vaccination
[9,12,18,37,38], could be a more effective strategy to
initially eradicate residual tumor cells while providing
sustained tumor immunity to prevent relapse.
The inability of adoptively transferred cells from
the reconstituted vaccinated mice that survived tumor
challenge to improve the survival rate of recipient
mice (Figure 6) reiterated the concept that DL and
bone marrow-derived cells are not adequately and/or
sufficiently modulated by a single pre-BMT treatment.
On the other hand, host immune cells, which constitute
only a small percentage of the post-BMT reconstituted
recipient after myeloablative conditioning (and most
likely cannot be adoptively transferred in sufficient
quantities), are primary to this vaccination approach.
The fact that we successfully implemented this
immunotherapy in a syngeneic BMT model is also
clinically important because of the absence of allogeneic
T cell-induced GVHD. However, in other murine
models [9,10], and also in a recent clinical trial that
involved the use of multiple administration of a GM-
CSF–secreting leukemia vaccine after allogeneic BMT
(days 30-35) [12], the approach was used both safely
and efficaciously. For this reason, one can speculate
that our pre-BMT vaccination strategy, which relies
more on host T cells, could be used in combination
with an allogeneic graft containing fewer DL, capable
of further potentiating the GVL effect of the vaccine,
while diminishing or eliminating the incidence of
GVHD. Further studies using pre-BMT vaccination
along with titrated numbers of allogeneic DL and
BMT should provide additional understanding of the
efficacy of such a combined therapy.
In summary, we demonstrated that a single pre-
BMT injection of GM-MMB3.19 cells significantly
increased the survival of syngeneic transplanted
MMB3.19-challenged mice. These results are highly
relevant to the clinical setting because harvesting large
amounts of tumor for the preparation of multiple
immunization dosages could be a difficult, time-
consuming, and costly task, making this pre-BMT
vaccination strategy more advantageous to achievesignificant tumor immunity. Furthermore, because
our methodology bypassed de novo immune reconsti-
tution, it actually becomes highly attractive for elderly
patients undergoing BMTwho are likely to experience
difficulties in reconstituting their T cell repertoire be-
cause of diminished thymic function. The improved
survival rate of GM-MMB3.19–treated mice was
shown to be strongly dependent on host T cells and
was also most likely related to an increased presence
of host-derived CD11c1 DCs. Finally, the strength
and duration of the GVL response induced by this vac-
cination were subject to the delivery site, with more
enduring protection obtained by s.c. injection.ACKNOWLEDGMENTS
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